Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.
The medical technology company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. The company's performance was driven by strong growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.
In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant after-hours stock price increase.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。